Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies

Trial Profile

Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary) ; Sonidegib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 May 2016 Status changed from active, no longer recruiting to recruiting.
    • 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top